Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06603558 | RECRUITING | Chronic Migraine

Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
Sponsor:

AbbVie

Brief Summary:

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice. Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 3000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in Korea. Participants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 12. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Condition or disease

Chronic Migraine

Episodic Migraine

Migraine

Intervention/treatment

Atogepant

Study Type : OBSERVATIONAL
Estimated Enrollment : 3000 participants
Official Title : Post-marketing Surveillance Study to Evaluate the Safety and Effectiveness of Atogepant for the Prevention of Migraine in Korean Adult Patients
Actual Study Start Date : 2024-09-24
Estimated Primary Completion Date : 2029-05
Estimated Study Completion Date : 2029-05

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 19 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Participants with migraine suitable for the treatment with atogepant according to the latest approved local label.
  • * Participants prescribed atogepant in accordance with the approved local label.
Exclusion Criteria
  • * Participants with any contraindication to atogepant as listed on the latest approved local label.
  • * Participants currently participating in another clinical research except observational study.
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

Location Details

NCT06603558

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

South Korea, Gyeonggi Do

Hallym University Dongtan Sacred Heart Hospital /ID# 273581

Hwaseong, Gyeonggi Do, South Korea, 18450

RECRUITING

South Korea, Seoul Teugbyeolsi

Seoul National University Hospital /ID# 271892

Seoul, Seoul Teugbyeolsi, South Korea, 03080

RECRUITING

South Korea, Seoul Teugbyeolsi

Pspital Priest /ID# 271893.

Seoul, Seoul Teugbyeolsi, South Korea, 03181

RECRUITING

South Korea, Seoul Teugbyeolsi

Yonsei University Health System Severance Hospital /ID# 272639

Seoul, Seoul Teugbyeolsi, South Korea, 03722